1971.7000 -59.00 (-2.91%)
NSE Sep 26, 2025 15:31 PM
Volume: 924.5K
 

1971.70
-2.91%
Deven Choksey
We have revised our FY26E/FY27E EPS estimates by -1.1 %/+13.2%, respectively, as we factor in improvement in EBITDA margins on account of improving mix and launch of high margin products.
Glenmark Pharmaceuticals Ltd. is trading above its 200 day SMA of 1653.1
More from Glenmark Pharmaceuticals Ltd.
Recommended